Freedom Insurance (FIG)

Size: px
Start display at page:

Download "Freedom Insurance (FIG)"

Transcription

1 03 November 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Medium Price Target $0.85 Share Price $0.50 SNAPSHOT Monthly Turnover $13.0mn Market Cap $169mn Shares Issued 239.7mn 52-Week High $ Week Low $0.34 Sector Financials BUSINESS DESCRIPTION FIG acts a specialist provider of products generally classed as Life Insurance under the relevant legislation in Australia such as life insurance, final expenses (funeral insurance), accidental death, accidental injury and mortgage protection. FIG seeks to design, manufacture, undertake marketing/lead generation, distribute and administer a simple range of products that are ideally suited to direct distribution and/or the general advice segment of third party distribution 12-MONTH PRICE & VOLUME RESEARCH ANALYST Nick Caley ncaley@baillieuholst.com.au Nicolas Burgess, CFA nburgess@baillieuholst.com.au Disclosure The author owns no shares in FIG. Baillieu Holst Ltd acted as Underwriter for FIG and earned fees in relation to that activity in the past 12 months. Freedom Insurance (FIG) COMPANY REPORT Expected halftime lead upset by leads 1H18 profit warning: FIG has announced that 1H18 EBITDA (ex the profit on sale of its Noble Oak investment) is likely to be in the range of A$7.5-$9.0m (our forecast was A$11.2m) versus A$11.1m in 1H17. FIG management commentary is that: 1) 1H18 net revenue is expected to be 3-11% higher versus 1H17 but largely due to trail commissions from the growing in-force book; 2) operating expenses of A$19-$20m for 1H18 will be in line with FIG s expectations and will include new product development; and 3) after a strong start to new sales in the traditional final expenses product, FIG cited a period in which it was adversely impacted by poor quality leads, which has negatively impacted conversion rates this has since been addressed with lead providers and FIG is citing a recovery to normal run rates by the end of 1H18. FIG expects new sales will be 9-15% lower than the pcp in 1H18. New product roll-out: FIG cited sales for new products of around A$1m for 1H18, which it states is in line with expectations. It has also signed an agreement with Peakbound Holdings to provide additional call centre capacity. FY18 outlook: FIG expects 2H18 earnings and sales to exceed 2H17 due to a larger in-force book, growth in sales and new products. Costs are expected to increase due to the investment in lead generation, marketing and infrastructure. Our view: A disappointing announcement for a company that had exceeded expectations since IPO. Our previous concern was that the launch of new products would detract from the focus of sales for the final expenses product. Management commentary suggests this has not been the case, with the quality of leads being the issue. We expect management to quickly correct this issue, although it appears this will leave a gap versus market expectations for FY18. Changes to forecasts: We have downgraded FY18/19/20 forecasts by 15%/11%/8% respectively. Investment view: BUY with revised DCF valuation of A$0.84 (prev.a$1.11) and price target of A$0.85 (prev. A$1.10). Whilst we expect today s announcement will depress FIG s share price for a number of months, we maintain our BUY call in view of: 1) valuation stock continues to trade on single-digit P/E despite today s downgrade; 2) management has vast experience in the Australian life insurance industry we are confident they will be quick to address events that have led to the downgrade; 3) focus on a range of simple products in a market where larger players have lost favour due to the complexity of products and general conduct; 4) new products likely to improve group average persistency due to premiums being paid in the first year; and 5) a debt free balance sheet with growing cash balance and low capital intensity. INVESTMENT SUMMARY Year End: 30 June 2016 (A) 2017 (A) 2018 (E) 2019 (E) 2020 (E) Revenue $mn EBITDA $mn EBIT $mn Reported Profit $mn Adjusted Profit $mn EPS (Reported) EPS (Adjusted) EPS Growth % PER (Reported) x PER (Adjusted) x Dividend Yield % Franking % Baillieu Holst Ltd ABN Please read the disclaimer at the end of this report. Page 1

2 Financial summary Freedom Insurance Group Analyst: Nick Caley Rating: BUY Date: 03-November-2017 Price target: $0.85 Current share price: $0.50 Valuation: $0.84 Year End: 30 June Risk: Medium PROFIT & LOSS (A$mn) FY16A FY17A FY18E FY19E FY20E Market Capitalisation A$m $169 Upfront Fee Revenue EARNINGS FY16A FY17A FY18E FY19E FY20E Trail Commission/Admin Fees EPS - Diluted Trail Asset Movement Normalised EPS Clawback Provision Management EPS Growth (%) 26% 337% -12% 28% 17% Adviser Commissions DPS Total Revenue Franking (%) Total Expenses Payout Ratio (%) n/a 0% 0% 0% 0% EBITDA Depreciation & Amortisation VALUATION FY16A FY17A FY18E FY19E FY20E EBIT P/E (x) - Reported Net Interest Expense P/E (x) - Normalised NPBT Dividend Yield (%) n/a 0.0% 0.0% 0.0% 0.0% Income Tax Expense EV/EBITDA (x) NPAT - Normalised Price/Book (x) Normalisation Adjustments Price/NTA (x) NPAT - Statutory GROWTH FY16A FY17A FY18E FY19E FY20E Statutory EBITDA Revenue Growth (% pcp) 45% 81% 15% 15% 11% Less Trail Asset Movement Operating Exp. Growth (% pcp) 39% 42% 27% 8% 7% Less Clawback Provision EBITDA Growth (% pcp) - Statutory 62% 193% -3% 28% 17% Cash EBITDA EBITDA Growth (% pcp) - Cash n/a 4800% 21% 57% 31% BALANCE SHEET (A$mn) FY16A FY17A FY18E FY19E FY20E EBIT Growth (% pcp) 62% 193% -3% 28% 17% Current Assets NPBT Growth (% pcp) 45% 238% 0% 28% 17% Cash NPAT Growth (% pcp) 15% 370% 24% 11% 17% NPV Of Future Trail Commissions Normalised NPAT Growth (% pcp) 26% 285% 1% 28% 17% Other Total Current Assets MARGINS & RETURNS FY16A FY17A FY18E FY19E FY20E Non Current Assets EBITDA Margin % - Statutory 26% 42% 35% 39% 41% NPV Of Future Trail Commissions EBITDA Margin % - Cash 1% 18% 19% 26% 31% Other Assets ROIC % 33% 75% 76% 85% 91% Intangibles ROE % 45% 50% 26% 25% 23% Total Non Current Assets ROA % 34% 42% 24% 24% 23% Total Assets Effective Tax Rate % 39% 31% 30% 30% 30% Current Liabilities Payables GEARING FY16A FY17A FY18E FY19E FY20E Clawback Provision Net Debt (A$mn) Loans & Borrowings Net Debt/Equity (%) 26% Neg Neg Neg Neg Other Cash from Operations/EBITDA % -29% 39% 39% 47% 53% Total Current Liabilities Non Current Liabilities Operational FY16A FY17A FY18E FY19E FY20E Provisions New Annual Premium Inflows A$m Deferred Tax In Force Annual Premium Income A$m Loans & Borrowings Other New Business - Annual Premium Inflows Total Non Current Liabilities Protection Plan (Final Expenses) Total Liabilities Premium Life/Freedom Essential Life Contributed Capital Loan Protection Reserves Total Retained Earnings Minority Interests Total Equity CASH FLOW (A$mn) FY16A FY17A FY18E FY19E FY20E Cash at Start Cash Flow from Ops Cash Flow From Investing Cash Flow From Financing Net Cash Flow Cash At End Baillieu Holst Ltd ABN Please read the disclaimer at the end of this report. Page 2

3 FIG.1: FIG 1H18 GUIDANCE Source: FIG Baillieu Holst Ltd ABN Please read the disclaimer at the end of this report. Page 3

4 Appendix FIG.2: LONG TERM MOMENTUM INDICATORS Source: Iress FIG.3: SHORT TERM MOMENTUM INDICATORS Source: Iress Baillieu Holst Ltd ABN Please read the disclaimer at the end of this report. Page 4

5 This document has been prepared and issued by: Baillieu Holst Ltd ABN Australian Financial Service Licence No Participant of ASX Group Participant of NSX Ltd Analysts stock ratings are defined as follows: Buy: The stock s total return is expected to increase by at least percent from the current share price over the next 12 months. Hold: The stock s total return is expected to trade within a range of ±10-15 percent from the current share price over the next 12 months. Sell: The stock s total return is expected to decrease by at least percent from the current share price over the next 12 months. Baillieu Holst Analysts stock ratings distribution as of 05 September 2017: Buy: 64% Hold: 32% Sell: 4% Disclosure of potential interest and disclaimer: Baillieu Holst Ltd (Baillieu Holst) and/or its associates may receive commissions, calculated at normal client rates, from transactions involving securities of the companies mentioned herein and may hold interests in securities of the companies mentioned herein from time to time. Your adviser will earn a commission of up to 55% of any brokerage resulting from any transactions you may undertake as a result of this advice. When we provide advice to you, it is based on the information you have provided to us about your personal circumstances, financial objectives and needs. If you wish to rely on our advice, it is important that you inform us of any changes to your personal investment needs, objectives and financial circumstances. If you do not provide us with the relevant information (including updated information) regarding your investment needs, objectives and financial circumstances, our advice may be based on inaccurate information, and you will need to consider whether the advice is suitable to you given your personal investment needs, objectives and financial circumstances. Please do not hesitate to contact our offices if you need to update your information held with us. Please be assured that we keep your information strictly confidential. No representation, warranty or undertaking is given or made in relation to the accuracy of information contained in this advice, such advice being based solely on public information which has not been verified by Baillieu Holst Ltd. Save for any statutory liability that cannot be excluded, Baillieu Holst Ltd and its employees and agents shall not be liable (whether in negligence or otherwise) for any error or inaccuracy in, or omission from, this advice or any resulting loss suffered by the recipient or any other person. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Baillieu Holst Ltd assumes no obligation to update this advice or correct any inaccuracy which may become apparent after it is given. Baillieu Holst Ltd ABN Australian Financial Service Licence No Participant of ASX Group Participant of NSX Ltd Melbourne (Head Office) Address Level 26, 360 Collins Street Melbourne, VIC 3000 Australia Postal PO Box 48, Collins Street West Melbourne, VIC 8007 Australia Phone Facsimile melbourne@baillieuholst.com.au Adelaide Office Address Ground Floor, 226 Greenhill Road, Eastwood SA 5063 Postal PO Box 171 Fullarton SA 5063 Phone Facsimile adelaide@baillieuholst.com.au Bendigo Office Address Level 1, Forest Street Bendigo, VIC 3550 Postal PO Box 84 Bendigo, VIC 3552 Phone Facsimile bendigo@baillieuholst.com.au Geelong Office Address 16 Aberdeen Street Geelong West Vic 3218 Postal PO Box 364 Geelong Vic 3220 Australia Phone Facsimile geelong@baillieuholst.com.au Gold Coast Office Address Suite 202 Level 2, Eastside Building 6 Waterfront Place, Robina QLD 4226 Phone Facsimile goldcoast@baillieuholst.com.au Newcastle Office Address Level 1, 120 Darby Street Cooks Hill, NSW 2300 Australia Postal PO Box 111 The Junction, NSW 2291 Australia Phone Facsimile newcastle@baillieuholst.com.au Perth Office Address Level 10, 191 St Georges Terrace Perth WA 6000 Australia Postal PO Box 7662, Cloisters Square Perth, WA 6850 Australia Phone Facsimile perth@baillieuholst.com.au Sydney Office Address Level 40, 259 George Street Sydney, NSW 2000 Australia Postal PO Box R1797 Royal Exchange, NSW 1225 Australia Phone Facsimile sydney@baillieuholst.com.au Baillieu Holst Ltd ABN Page 5

Praemium (PPS) COMPANY REPORT. Model performance

Praemium (PPS) COMPANY REPORT. Model performance 14 August 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.41 SNAPSHOT Monthly Turnover $9.5mn Market Cap $165mn Shares Issued 398.5mn 52-Week High $0.54 52-Week

More information

Vita Group (VTG) COMPANY REPORT. Vitality in question

Vita Group (VTG) COMPANY REPORT. Vitality in question 18 May 2017 INTERNAL ONLY RECOMMENDATIONS Rating HOLD Risk High Price Target $0.85 Share Price $0.90 SNAPSHOT Monthly Turnover $79.4mn Market Cap $137mn Shares Issued 152.6mn 52-Week High $5.47 52-Week

More information

Insurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates

Insurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates 11 May 2018 RECOMMENDATIONS AUB Group (AUB) Rating HOLD Risk Low Price Target $14.50 Share Price $14.17 Steadfast Group (SDF) Rating HOLD Risk Low Price Target $2.80 Share Price $2.88 RESEARCH ANALYST

More information

Praemium (PPS) COMPANY REPORT. Quartermaster

Praemium (PPS) COMPANY REPORT. Quartermaster 10 October 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.45 SNAPSHOT Monthly Turnover $9.2mn Market Cap $162mn Shares Issued 399.6mn 52-Week High $0.54 52-Week

More information

SeaLink Travel Group (SLK)

SeaLink Travel Group (SLK) 29 June 2018 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Medium Price Target $5.10 Share Price $4.45 SNAPSHOT Monthly Turnover $9.3mn Market Cap $446mn Shares Issued 101.2mn 52-Week High $4.46 52-Week

More information

APN Outdoor Group (APO)

APN Outdoor Group (APO) 26 June 2018 INTERNAL ONLY RECOMMENDATIONS Rating HOLD Risk Medium Price Target $6.70 Share Price $6.45 SNAPSHOT Monthly Turnover $323.7mn Market Cap $1,069mn Shares Issued 167.0mn 52-Week High $6.70 52-Week

More information

Genex Power (GNX) COMPANY REPORT. NAIF lined up for Stage 2

Genex Power (GNX) COMPANY REPORT. NAIF lined up for Stage 2 21 June 2018 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Speculative Price Target $0.37 Share Price $0.31 SNAPSHOT Monthly Turnover $2.5mn Market Cap $91mn Shares Issued 303.9mn 52-Week High $0.43 52-Week

More information

Pacific Energy (PEA)

Pacific Energy (PEA) 01 December 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.69 Share Price $0.58 SNAPSHOT Monthly Turnover $5.6mn Market Cap $223mn Shares Issued 371.8mn 52-Week High $0.77 52-Week

More information

Appen (APX) COMPANY REPORT

Appen (APX) COMPANY REPORT 11 January 2018 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $10.00 Share Price $8.63 SNAPSHOT Monthly Turnover $89.8mn Market Cap $895mn Shares Issued 105.8mn 52-Week High $8.96 52-Week

More information

Bass Metals (BSM) COMPANY REPORT INITIATION OF COVERAGE. Starting small in graphite

Bass Metals (BSM) COMPANY REPORT INITIATION OF COVERAGE. Starting small in graphite 6 February 218 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Speculative Price Target $.7 Share Price $.2 SNAPSHOT Monthly Turnover $5.4mn Market Cap $46mn Shares Issued 2,213.4mn 52-Week High $.3 52-Week

More information

Gold Road Resources (GOR)

Gold Road Resources (GOR) 24 November 215 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Speculative Price Target $.47 Share Price $.37 SNAPSHOT Monthly Turnover $6.7mn Market Cap $26mn Shares Issued 693.5mn 52-Week High $.48 52-Week

More information

Australian Strategy Insight

Australian Strategy Insight 21 March 218 INTERNAL ONLY CHIEF INVESTMENT OFFICER Malcolm Wood +61 2 925 8916 mwood@baillieuholst.com.au Australian Strategy Insight INVESTMENT STRATEGY US starting to outstrip Australia Over the past

More information

Kibaran Resources (KNL)

Kibaran Resources (KNL) 26 March 218INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Speculative Price Target $.23 Share Price $.13 SNAPSHOT Monthly Turnover $.4mn Market Cap $32mn Shares Issued 244.4mn 52-Week High $.21 52-Week

More information

Asset Allocator INVESTMENT STRATEGY. Extreme Underweight

Asset Allocator INVESTMENT STRATEGY. Extreme Underweight 27 June 2018 INTERNAL ONLY CHIEF INVESTMENT OFFICER Malcolm Wood +61 2 9250 8916 mwood@baillieuholst.com.au Asset Allocator INVESTMENT STRATEGY Reducing Australian equities; adding to International Year-to-date

More information

Pacific Energy (PEA)

Pacific Energy (PEA) 11 August 2016 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.73 Share Price $0.64 SNAPSHOT Monthly Turnover $2.1mn Market Cap $235mn Shares Issued 370.2mn 52-Week High $0.65 52-Week

More information

Hybrids Daily. Commentary on yesterday s market FIG.1: UP FIG.2: DOWN FIG.3: BEST SWITCH FIG.4: UPCOMING DISTRIBUTIONS FIG.5: THE SWAP CURVE 2.

Hybrids Daily. Commentary on yesterday s market FIG.1: UP FIG.2: DOWN FIG.3: BEST SWITCH FIG.4: UPCOMING DISTRIBUTIONS FIG.5: THE SWAP CURVE 2. Interest Rate BAILLIEU HOLST RESEARCH 13 April 2016 INTERNAL ONLY Hybrids Daily Commentary on yesterday s market Business conditions have soared to the highest level in eight years, according to NAB, with

More information

Hybrids Daily. Commentary on yesterday s market FIG.1: UP FIG.2: DOWN FIG.3: BEST SWITCH FIG.4: UPCOMING DISTRIBUTIONS FIG.5: THE SWAP CURVE 3.

Hybrids Daily. Commentary on yesterday s market FIG.1: UP FIG.2: DOWN FIG.3: BEST SWITCH FIG.4: UPCOMING DISTRIBUTIONS FIG.5: THE SWAP CURVE 3. Interest Rate BAILLIEU HOLST RESEARCH 30 June 2016 INTERNAL ONLY Hybrids Daily Commentary on yesterday s market Germany's financial market regulator has delivered a double blow to London, saying it could

More information

Zip Co. Delivering against expectations. Last Price A$0.86 Target Price A$0.90 (Previously A$0.88) Recommendation Accumulate Risk Higher.

Zip Co. Delivering against expectations. Last Price A$0.86 Target Price A$0.90 (Previously A$0.88) Recommendation Accumulate Risk Higher. Delivering against expectations Z1P s Mar-18 qtrly report delivered well against our expectations. Positive operating cash flow for the qtr of $1.6m was a +$2.8m improvement qoq, despite the receivables

More information

Company Review. Centaurus Metals. Jambreiro Resource upgrade. CTM A$0.08 Recommendation Buy Risk Assessment High

Company Review. Centaurus Metals. Jambreiro Resource upgrade. CTM A$0.08 Recommendation Buy Risk Assessment High Company Review Ord Minnett Research Friday, June 24, 2011 Centaurus Metals Jambreiro Resource upgrade Centaurus has upgraded the JORC resource at its flagship, Jambreiro Iron Ore Project in Brazil. The

More information

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD

More information

Australian Equity Research

Australian Equity Research 8 March 2018 Australian Equity Research MARCH 2018 Top Stock Picks Mid & Small Caps Overall: We select the top picks from our 86 mid and small cap universe, as well as the outlook for the economy and equity

More information

Consolidated Operations Group (COG)

Consolidated Operations Group (COG) Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation

More information

MacPhersons Resources (MRP)

MacPhersons Resources (MRP) 07 May 2012 RECOMMENDATIONS Rating BUY Risk Very High Price Target $0.59 Share Price $0.40 SNAPSHOT Monthly Turnover $3.1mn Market Cap $85mn Shares Issued 215mn 52-Week High $0.41 52-Week Low $0.23 Sector

More information

Zip Co. Improved medium term cost guidance. Last Price A$0.96 Target Price A$1.00 (Previously A$0.90) Recommendation Accumulate Risk Higher

Zip Co. Improved medium term cost guidance. Last Price A$0.96 Target Price A$1.00 (Previously A$0.90) Recommendation Accumulate Risk Higher Improved medium term cost guidance Z1P s Jun-18 qtrly update outlined a beat against our cash flow expectations, with the company having generated positive operating cash flow (after bad debts) for the

More information

Company Review 1300SMILES. Corporate Activity Dental Partners. ONT A$6.72 (TP $6.26) Recommendation Hold (no change) Risk Assessment Medium

Company Review 1300SMILES. Corporate Activity Dental Partners. ONT A$6.72 (TP $6.26) Recommendation Hold (no change) Risk Assessment Medium Ord Minnett Research 2 October 2013 1300SMILES Corporate Activity Dental Partners Event: A consortium led by private equity firm, Archer Capital has recently made an indicative offer for 100% of New Zealand

More information

SPS Managed Portfolios Aust Equities Income Portfolio

SPS Managed Portfolios Aust Equities Income Portfolio SPS Managed Portfolios Aust Equities Income Portfolio For further information on Baillieu Holst s Discretionary SPS Managed Portfolios, contact your adviser or email your details to Strategic Planning

More information

MNF Group Limited (MNF)

MNF Group Limited (MNF) MNF Group Limited (MNF) 16 February 2018 Outperform 1H18 Results: Excessive Sell-off Presents Buying Opportunity $5.14 Chris Reindler creindler@taylorcollison.com.au +61 2 9210 1335 Summary (AUD) Market

More information

Regional Express Holdings Ltd REX

Regional Express Holdings Ltd REX 20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last

More information

Pinnacle Investment Management

Pinnacle Investment Management The pinnacle of execution Pinnacle provided a FUM update and 1H18 guidance which were both well ahead of our expectation, driven by rapid retail and insto inflows. FUM at Dec-17 of $32.4b sits above our

More information

MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts

MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts Date Theme Company Update Company MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction We moderate to HOLD (from Buy) with a revised target of $2.36 p/share. We were previously encouraged

More information

WINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW

WINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital

More information

Wisr Ltd (DirectMoney)

Wisr Ltd (DirectMoney) Wisr Ltd (DirectMoney) Interim result draws a line in the sand Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace-lending sector. The company has

More information

Listed Investment Companies (LICs)

Listed Investment Companies (LICs) 21 March 218 CONTENTS Company Page # LIC Sector Picks 1 Updated Sector Snapshot 2 LIC Table 3 Top Picks AFIC (AFI) 4 Diversified United (DUI) 5 WAM Leaders (WLE) 6 Acorn Capital (ACQ) 7 Templeton Global

More information

Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions

Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions 16 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation TS Lim 612 8224 2810 Perpetual (PPT) Oversold, upgrade to Buy Recommendation Buy (Hold) Price $42.09 Target (12 months) $47.50 (previously

More information

Big River Industries Limited (ASX:BRI)

Big River Industries Limited (ASX:BRI) Big River Industries Limited (ASX:BRI) FY2018 Half Year Results Briefing 27 February 2018 Optus Stadium - Perth H1 FY2018 - Contents 1. Highlights 2. Business Diversity Strengthening 3. Sales Highlights

More information

Resetting expectations

Resetting expectations Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp

More information

Tabcorp Holdings Limited. 2014/15 Full Year Results Presentation 13 August 2015

Tabcorp Holdings Limited. 2014/15 Full Year Results Presentation 13 August 2015 Tabcorp Holdings Limited ABN 66 063 780 709 2014/15 Full Year Results Presentation 13 August 2015 Draft version 15 (01-08-13) FY15 overview Statutory NPAT $334.5m, up 157.5%, comprising of: NPAT from continuing

More information

Asset revaluation driven by almonds

Asset revaluation driven by almonds Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of

More information

Wisr Ltd (DirectMoney)

Wisr Ltd (DirectMoney) Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The

More information

Invocare. Well-positioned. Earnings and target price revision. Price catalyst. Catalyst: FY12 results. Action and recommendation

Invocare. Well-positioned. Earnings and target price revision. Price catalyst. Catalyst: FY12 results. Action and recommendation AUSTRALIA IVC AU Close Price* 19 Jan 12 Outperform A$7.54 Volatility index Low 12-month target A$ 8.3 12-month TSR % +14.6 Valuation A$ 8.28 - DCF GICS sector Consumer Services Market cap A$m 83 3-day

More information

Company Review. Horizon Oil Limited (HZN) FY14 results full year China impact. Last price $0.34

Company Review. Horizon Oil Limited (HZN) FY14 results full year China impact. Last price $0.34 Ord Minnett Research 1 September (HZN) FY14 results full year China impact Valuation and Recommendation We retain our Buy recommendation and have revised our target price to $0.45/sh (prev. $0.53/sh) after

More information

H1 FY15 Results Presentation

H1 FY15 Results Presentation H1 FY15 Results Presentation 10 February 2015 Andrew Grech Group Managing Director Wayne Brown CFO Ken Fowlie CEO Australia 1 Disclaimer This document has been prepared by Slater and Gordon Limited (Slater

More information

APN Property Group (APD) Buy Share Price: A$0.41

APN Property Group (APD) Buy Share Price: A$0.41 APN Property Group (APD) Buy Share Price: A$0.41 Success in direct syndicates Target Price: A$0.51 Direct property syndicates have always been an integral part of the APN Property Group (APD) business.

More information

Platinum Asset Management

Platinum Asset Management AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium

More information

26 November Company Announcements Office Australian Securities Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000

26 November Company Announcements Office Australian Securities Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000 26 November 2013 Company Announcements Office Australian Securities Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000 Aristocrat Leisure Limited 2013 Aristocrat Leisure Limited will make

More information

Noni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts

Noni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in

More information

Wisr Ltd. New products to underpin growth

Wisr Ltd. New products to underpin growth Wisr Ltd Company Update New products to underpin growth Wisr Limited (WZR.AX) is an online consumer lending platform focused on financial wellness and competing in the rapidly growing marketplace lending

More information

AtCor Medical Holdings Limited (ACG)

AtCor Medical Holdings Limited (ACG) Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary

More information

For personal use only

For personal use only Annual General Meeting Managing Director Presentation Jamie Pherous 31 October 2011 Disclaimer While every care has been taken in the preparation of this presentation, Corporate Travel Management (CTM)

More information

COMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW

COMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW COMPUMEDICS LTD HOLD CMP Downgrades FY17 Guidance Health Care Equipment & Services / Health Care Equipment 7 July 2017 COMPANY UPDATE Ticker CMP Stock Price $0.560 Target Price $0.530 Forecast Capital

More information

Tabcorp Holdings Limited 2015/16

Tabcorp Holdings Limited 2015/16 Tabcorp Holdings Limited ABN 66 063 780 709 2015/16 Full Year Results Presentation 4 August 2016 Draft version 15 (01-08-13) FY16 overview Statutory results NPAT $169.7m, down 49.3% EPS 20.4 cents per

More information

Cardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

Cardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation AUSTRALIA CDD AU Price (at 04:53, 17 Feb 2015 GMT) Neutral A$2.88 Valuation - Sum of Parts A$ 2.80-3.43 12-month target A$ 3.12 12-month TSR % +18.4 Volatility Index Medium GICS sector Capital Goods Market

More information

Monash IVF Group. FY16 Results Presentation 26 August 2016

Monash IVF Group. FY16 Results Presentation 26 August 2016 Monash IVF Group FY16 Results Presentation 26 August 2016 Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ( MVF ) (including its subsidiaries, affiliates and

More information

Adacel Technologies (ADA)

Adacel Technologies (ADA) 9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously

More information

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA NHF AU Price (at 09:52, 02 Mar 2016 GMT) Outperform A$3.72 Valuation A$ 3.85 - DCF (WACC 8.5%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 2.5%) 12-month target A$ 4.00 12-month TSR % +11.7 Volatility

More information

CogState Limited (CGS)

CogState Limited (CGS) CogState Limited (CGS) 26 August 2010 Outperform FY10 NPAT of $1.6m; Launches Axon Sports JV $0.24 Thomas Duthy PhD MBA tduthy@taylorcollison.com.au +61 2 9377 1500 Summary Market Capitalisation (M) $15.8

More information

25 February The Manager Market Announcements Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000.

25 February The Manager Market Announcements Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000. Level 1 157 Grenfell Street Adelaide SA 5000 GPO Box 2155 Adelaide SA 5001 Adelaide Brighton Ltd ACN 007 596 018 Telephone (08) 8223 8000 International +618 8223 8000 Facsimile (08) 8215 0030 www.adbri.com.au

More information

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation 1H13E 2H13E 1H14E 2H14E 1H15E 2H15E AUSTRALIA CGF AU Price (at CLOSE#, 20 Aug 2012) Outperform A$3.76 Volatility index Low 12-month target A$ 4.57 12-month TSR % +26.4 Valuation - Sum of Parts A$ 4.57

More information

Aveo presentation at Morgans Queensland Conference 2016

Aveo presentation at Morgans Queensland Conference 2016 12 October 2016 Aveo presentation at Morgans Queensland Conference 2016 Australia s leading owner, operator and manager of retirement communities, Aveo Group Limited (ASX: AOG) today presented at the Morgans

More information

Sales increased 8.1% to $128.0m (HY17: $118.4m)

Sales increased 8.1% to $128.0m (HY17: $118.4m) Nick Scali Limited NCK.ASX HY18 Results Presentation 7th February 2018 Key Highlights Sales increased 8.1% to $128.0m (HY17: $118.4m) Sales Like for like sales growth of +2.6% for Nick Scali Furniture

More information

Sample. Virtus Health Ltd. Financial Analysis VRT $7.15. No Holding at Time of Report

Sample. Virtus Health Ltd. Financial Analysis VRT $7.15. No Holding at Time of Report Virtus Health Ltd Financial Analysis Date: VRT $7.15 Disclosure: Contact: W: www.pupresearch.com.au E: info@pupresearch.com.au T: +61 3 9214 2 1 5-Jul-213 No Holding at Time of Report VRT Overview Virtus

More information

PRICE $1.16 Regional Express Holdings Ltd REX

PRICE $1.16 Regional Express Holdings Ltd REX 13 September 2006 PRICE $1.16 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$121.9M

More information

FY2015 Annual Results August Brett McKeon - CEO David Bailey - CFO

FY2015 Annual Results August Brett McKeon - CEO David Bailey - CFO FY2015 Annual Results August 27 2015 Brett McKeon - CEO David Bailey - CFO FY2015 Financial Results Highlights Delivery on FY15 Prospectus forecasts Pro forma NPAT $19.3 million up 8.4% against IPO forecast

More information

Codan Ltd (CDA) EQUITY RESEARCH Information Technology. Solid first half momentum, positioned for even better second.

Codan Ltd (CDA) EQUITY RESEARCH Information Technology. Solid first half momentum, positioned for even better second. Feb 17 Mar 17 Apr 17 May 17 Jul 17 Aug 17 Sep 17 Oct 17 Nov 17 Dec 17 Jan 18 Feb 18 EQUITY RESEARCH Information Technology 26 February 2018 Codan Ltd (CDA) Solid first half momentum, positioned for even

More information

For personal use only

For personal use only 23 August 2013 Full Year Results June 2013 We attach an Investor Presentation for the FY13 Full Year Results. As previously announced, a results briefing for analysts will be held at 10:30am Sydney time

More information

Tatts Group. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Underperform on valuation grounds.

Tatts Group. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Underperform on valuation grounds. AUSTRALIA TTS AU Price (at 8:37, 23 Aug 212 GMT) Underperform A$2.79 Volatility index Low 12-month target A$ 2.45 12-month TSR % -6.8 Valuation - Sum of Parts A$ 2.4-2.47 GICS sector Consumer Services

More information

For personal use only. Mantra Group. FY2015 Results Presentation 27 August 2015

For personal use only. Mantra Group. FY2015 Results Presentation 27 August 2015 Mantra Group FY2015 Results Presentation 27 August 2015 IMPORTANT NOTICE AND DISCLAIMER Important notice and disclaimer This document is a presentation of general background information about the activities

More information

Mantra Group Limited (ASX Code: MTR) ABN Annual General Meeting 22 November 2017

Mantra Group Limited (ASX Code: MTR) ABN Annual General Meeting 22 November 2017 Mantra Group Limited (ASX Code: MTR) ABN 69 137 639 395 2017 Annual General Meeting 22 November 2017 Chairman s Address Peter Bush Good Morning, and welcome to the 2017 Mantra Group Annual General Meeting.

More information

Credit Suisse Annual Asian Investment Conference

Credit Suisse Annual Asian Investment Conference Adelaide Brighton Limited Credit Suisse Annual Asian Investment Conference Hong Kong, 27 30 March 2017 Martin Brydon Chief Executive Officer and Managing Director Adelaide Brighton Limited Overview of

More information

Noni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts

Noni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of

More information

Negotiating Cyclone project buy in

Negotiating Cyclone project buy in 4 July 2017 Negotiating Cyclone project buy in Cape Bedford : High quality silica sand Recommendation Strong BUY, High Risk Price Valuation Products : 0.7c 6.5c Mineral Sands (Zircon rich) Silica sand

More information

For personal use only

For personal use only IMPORTANT NOTICE AND DISCLAIMER Important notice and disclaimer This document is a presentation of general background information about the activities of Mantra Group Limited (Mantra Group) current at

More information

Genworth Mortgage Insurance Australia

Genworth Mortgage Insurance Australia Genworth Mortgage Insurance Australia 1Q 2016 Financial results presentation 29 April 2016 2016 Genworth Mortgage Insurance Australia Limited. All rights reserved. Disclaimer This presentation contains

More information

For personal use only. FY2017 H1 Results February 2017

For personal use only. FY2017 H1 Results February 2017 For personal use only FY2017 H1 Results February 2017 The half year in review Broader automotive market supported by record new vehicle sales in Australia and New Zealand Strong Automotive earnings growth

More information

The quiet achiever. Earnings and target price revision. Price catalyst. Catalyst: July building approvals 30 August. Action and recommendation

The quiet achiever. Earnings and target price revision. Price catalyst. Catalyst: July building approvals 30 August. Action and recommendation AUSTRALIA ABC AU Price (at 08:02, 16 Aug 2012 GMT) Outperform A$2.90 Volatility index Low/Medium 12-month target A$ 3.10 12-month TSR % +13.0 Valuation A$ 3.18 - DCF (WACC 10.0%, beta 1.2, ERP 4.5%, RFR

More information

MIRVAC GROUP 3 MAY Management Update INCLUDING 3Q16 HIGHLIGHTS

MIRVAC GROUP 3 MAY Management Update INCLUDING 3Q16 HIGHLIGHTS MIRVAC GROUP 3 MAY 2016 Management Update INCLUDING 3Q16 HIGHLIGHTS URBAN FOCUS > We are an urban company, we create places for people to live, work and shop > We understand the fabric of cities and the

More information

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016. AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium

More information

For personal use only

For personal use only Nick Scali Limited NCK.ASX FY18 Results Presentation 16 th August 2018 Key Highlights Sales Sales increased 7.7% to $250.8m (FY17: $232.9m) Increase assisted by full year of sales from 4 stores opened

More information

Full Year 2017 Results Presentation Bravura Solutions Limited

Full Year 2017 Results Presentation Bravura Solutions Limited Full Year 2017 Results Presentation Bravura Solutions Limited 23 rd August 2017 Important notice and disclaimer The information contained in this document (including this notice) or discussed at this presentation

More information

PRICE $1.30 Regional Express Holdings Ltd REX

PRICE $1.30 Regional Express Holdings Ltd REX 16 November 2006 PRICE $1.30 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115M Market cap A$133M

More information

OneVue Holdings (OVH)

OneVue Holdings (OVH) 7 August 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 OneVue Holdings (OVH) FY17 result to show cost-out progress Recommendation

More information

OneVue Holdings (OVH)

OneVue Holdings (OVH) 24 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation Peter Arden 613 9235 1833 OneVue Holdings (OVH) Restructured and focused Recommendation Buy (unchanged) Price $0.745 Target (12 months)

More information

Sims Metal Management

Sims Metal Management AUSTRALIA SGM AU Price (at 5:11, 17 Nov 215 GMT) Outperform A$7.19 Valuation - EV/EBIT A$ 8.49-9.6 12-month target A$ 8.9 12-month TSR % +26.6 Volatility Index Medium GICS sector Materials Market cap A$m

More information

Shaw and Partners is one of Australia s preeminent investment and wealth management firms.

Shaw and Partners is one of Australia s preeminent investment and wealth management firms. Contents Welcome...02 How to get started...03 Form...04 Information to read and retain Agreement...06 Shaw and Partners Limited Shaw and Partners is one of Australia s preeminent investment and wealth

More information

SKYCITY Entertainment Group Limited. FY16 Full-Year Result Presentation 10 August SKYCITY Entertainment Group Limited

SKYCITY Entertainment Group Limited. FY16 Full-Year Result Presentation 10 August SKYCITY Entertainment Group Limited SKYCITY Entertainment Group Limited FY16 Full-Year Result Presentation 10 August 2016 SKYCITY Entertainment Group Limited Disclaimer All information included in this presentation is provided as at 10 August

More information

INDEPTH RESEARCH NOTE REA Group Ltd Neutral

INDEPTH RESEARCH NOTE REA Group Ltd Neutral 1 INDEPTH RESEARCH NOTE REA Group Ltd Neutral Price: A$72.97 Price Target: A$74.80 ASX: REA 12 February 2018 REA s first half FY18 (1H18) result was underpinned by strong growth in the Australian business

More information

Platinum Asset Management (PTM)

Platinum Asset Management (PTM) 24 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Recommendation Hold (unchanged) Price $5.10 Target (12 months) $4.90

More information

UBS Investment Research Brambles Limited

UBS Investment Research Brambles Limited UBS Investment Research Brambles Limited FY12 result: strong revenue momentum Result highlights strong revenue momentum Brambles FY12 result was slightly ahead of expectations, revealing 11% underlying

More information

HALF YEAR RESULTS PRESENTATION

HALF YEAR RESULTS PRESENTATION ASX Announcement 16 February 2016 HALF YEAR RESULTS PRESENTATION Attached is the presentation regarding the financial results of The Star Entertainment Group Limited (The Star Entertainment Group) for

More information

Family Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation

Family Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation BW EQUITIES RESEARCH 14 March 2017 Family Zone Cyber Safety Limited (FZO) Company Update BUY Rating: Target Price 1 : $0.46 Projected Return: 109% 1 12 month target Company Statistics Share Price (A$)

More information

Codan Limited (ASX: CDA)

Codan Limited (ASX: CDA) Codan Limited (ASX: CDA) 1H18 Results March 2018 WHO IS IIR?, IIR, is an independent investment research house based in Australia and the United States. IIR specialises in the analysis of high quality

More information

Qube Holdings Limited

Qube Holdings Limited Qube Holdings Limited Investor Presentation FY 18 Interim Results 1 Disclaimer Important Notice ABN 141 497 230 53 The information contained in this Presentation or subsequently provided to the recipient

More information

Goldman Sachs JBWere Financial Services Guide

Goldman Sachs JBWere Financial Services Guide Goldman Sachs JBWere Financial Services Guide September 2007 Goldman Sachs JBWere Pty Ltd ABN 21 006 797 897 AFSL 243346 Goldman Sachs JBWere Capital Markets Limited ABN 97 004 463 263 AFSL 247175 Invia

More information

Genworth Mortgage Insurance Australia

Genworth Mortgage Insurance Australia AUSTRALIA GMA AU Price (at 07:29, 05 Aug 2015 GMT) Outperform A$3.50 Valuation A$ - DCF (WACC 12.0%, beta 1.6, ERP 5.0%, RFR 4.5%) 3.52 12-month target A$ 3.47 12-month TSR % +9.2 Volatility Index Medium

More information

Half Year Report EMPIRED LIMITED AND ITS CONTROLLED ENTITIES INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31ST DECEMBER 2016 ACN

Half Year Report EMPIRED LIMITED AND ITS CONTROLLED ENTITIES INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31ST DECEMBER 2016 ACN Half Year Report EMPIRED LIMITED AND ITS CONTROLLED ENTITIES INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31ST DECEMBER ACN 090 503 843 Contents Corporate Directory 3 Directors' Report 4 Statement

More information

The attached Revised FY2018 Results Presentation corrects this error.

The attached Revised FY2018 Results Presentation corrects this error. 29 November 2018 Company Announcements Office Australian Securities Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000 Aristocrat Leisure Limited Formatting Error Revised FY2018 Results

More information

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index

More information

Australian Banks. Insolent Insolvencies

Australian Banks. Insolent Insolvencies AUSTRALIA Insolvencies Stubborn # of Insolvencies 17, 16, 15, 14, 13, 12, 11, 1, Source: ASIC, Macquarie Research, Dec 212 WA/VIC insolvencies deterioration 2.4 2.2 Jan- 2 1.8 1.6 1.4 1.2 1 Source: ASIC,

More information

For personal use only

For personal use only DWS Limited 2018 Full Year Results Presentation Contents Introduction Danny Wallis (CEO) / Stuart Whipp (CFO) Results Highlights Full Year Results Capital Management Operations Update Summary and Outlook

More information

MEDICAL DEVELOPMENTS INTERNATIONAL LTD

MEDICAL DEVELOPMENTS INTERNATIONAL LTD MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08

More information